
The study has revealed the effectiveness of injectable cabotegravir in preventing HIV among transgender women. The study enrolled 570 transgender women, with a significant representation from Asia and Latin America. The results also highlighted the importance of addressing social and structural vulnerabilities, as intimate partner violence and abuse were prevalent. Injectable cabotegravir was a safe and effective pre-exposure prophylaxis option, with a significantly lower HIV incidence than the standard treatment.
Like
Save
Share